Congress Overview

The American Cancer Society (ACS) estimates that 228,150 new cases of lung cancer will be diagnosed in the United States in 2019 with an estimated 142,670 estimated deaths, with smoking remaining an important risk factor. The emergence of new biomarker testing, advances in radiation techniques, and the availability of new systemic therapies has changed the treatment landscape for non-small cell lung cancer.  This rapid pace of development and evolution has created challenges for clinicians to remain current with the advances in treatment options and the management of adverse events resulting from these new therapies. The NCCN 2019 Congress Series™: Lung Cancer is designed to familiarize clinicians with key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), new and emerging therapeutic options, the latest clinical research on lung cancer, and how these advances compare to the current standard of care to optimize management of patients with lung cancer and assist practitioners to incorporate new cancer treatment strategies and regimens into their practice.

Congress Goal: The goal of this congress is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with lung cancer and those being screened for lung cancer.

Intended Audience

This educational program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant health care professionals who manage the care of patients with lung cancer. 

Educational Objectives

Following this program, participants should be able to:


Biomarker Testing in Non-Small Cell Lung Cancer
  • Review new recommendations for biomarker testing to improve outcomes of patients with metastatic non-small cell lung cancer.
  • Discuss recommended biomarker testing methodologies for patients with metastatic non-small cell lung cancer.
  • Determine when it is appropriate to use liquid biopsies to guide treatment selection.

Radiation Techniques in the Treatment of Lung Cancer
  • Describe the role of stereotactic ablative radiation therapy in patients with early-stage non-small cell lung cancer.
  • Recommend appropriate consolidation immunotherapy after treatment with concurrent chemoradiation in patients with unresectable stage III non-small cell lung cancer.
  • Recognize how to decrease toxicity in patients with non-small cell lung cancer receiving concurrent chemoradiation.

Immunotherapies in Non-Small Cell Lung Cancer
  • Identify the different immunotherapy regimens for patients with non-small cell lung cancer.
  • Describe appropriate sequencing of therapy in patients with non-small cell lung cancer who have received immunotherapy regimens.
  • Discuss the potential for immune-mediated adverse events with other health care providers and patients receiving immunotherapy.

Smoking Cessation in Patients with Cancer
  • Describe the key elements of a smoking cessation treatment plan, including pharmacotherapy and behavior therapy.
  • Apply the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to assess and document patient smoking history and recommend appropriate cessation treatment.
  • Counsel patients about the impact of smoking and the benefits of smoking cessation on cancer treatment and patient outcomes.

New Targeted Therapies for Non-Small Cell Lung Cancer
  • Select appropriate targeted therapies for patients with metastatic non-small cell lung cancer who have oncogenic driver mutations.
  • Develop appropriate treatment strategies for patients with metastatic non-small cell lung cancer who have progressed on targeted therapies.
  • Discuss targeted therapy with their patients with metastatic non-small cell lung cancer including the need to monitor for adverse side effects.

Accreditation Statements

Jointly Accreditation Logo 

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Eduction (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 4.75 contact hours.

Pharmacists
NCCN designated this knowledge-based continuing education activity for 4.75 contact hours (0.475 CEUs) of continuing education credit. UAN: JA4008196-0000-19-079-L01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA CAtegory 1 CME credit for activities planned in accordance with AAPA CMA Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

CME-MOC graphic 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification (MOC)

ABPath Logo 

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Maintenance of Certification program. Successful completion of this CME activity enables the participant to earn up to 4.75 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties (MOC)

Through the American Board of Medical Specialties (ABMS) MOC initiative to create a wide array of Maintenance of Certification ("MOC") Activities through the ABMS MOC Directory, the NCCN 2019 Congress Series: Lung Cancer has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the followin ABMS Member Boards:

MOC Part II CME Activity
Radiology

Requirements for receiving CE credit

Before or during the congress, please ensure that you have an NCCN account and will receive the correct type of credit. 

  1. Log in at http://www.nccn.org
    • If you do not have an NCCN account, click “Sign up here” to create one for free.
  2. Click “Profile” in the left side menu.
  3. Verify that your User Type matches the type of credit you will claim:
    • Physician/Surgeon/Oncologist = physician credits; ABIM or ABPath MOC points, if applicable*
    • Pharmacist = pharmacist CEUs**
    • Nurse Practitioner = nurse contact hours; physician credits
    • Clinical Nurse Specialist = nurse contact hours
    • Nurse/Oncology Nurse = nurse contact hours
    • Case Manager (Nurse) = nurse contact hours
    • All other user types = certificate of participation
  4. Scroll down and click “Save” if you make any changes

Within 5 business days of this educational activity, you will receive an e-mail with instructions on how to complete the CE requirements online through NCCN’s Continuing Education Portal (http://education.nccn.org). Within 30 days of the activity, you must:

  • Attend the activity
  • Complete the immediate post-test
  • Complete the evaluation
  • Claim your credits

You will be able to view/print your certificate online once all requirements have been met.

*Physicians claiming ABIM/ABPath MOC points: MOC points are reported to ABIM and ABPath once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your ABIM/ABPath learner ID and date of birth. Your credit cannot be reported without this information.

**Pharmacists: You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Your credit cannot be reported without this information.

If you have any questions, please e-mail education@nccn.org.


NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top